Aeterna Zentaris to Present Preclinical Data for PI3K/Erk 1/2 Inhibitor, AEZS-136, at ACS National Meeting
QUÃ‰BEC CITY, Aug. 13, 2012 /PRNewswire/ – Aeterna Zentaris Inc. (NASDAQ:
AEZS) (TSX: AEZ) (the ”Company”) today announced that its V.P.,
Medicinal Chemistry, Matthias Gerlach, PhD, will be making a poster
presentation on preclinical results for the Company’s novel orally
active anticancer PI3K/Erk 1/2 inhibitor, AEZS-136, during the 244(th) National Meeting of the American Chemistry Society which will be held
August 19-23, 2012, in Philadelphia.
Poster #46: "Dual PI3K/Erk Inhibitor AEZS-136, A Potent Anti-Tumor Compound Under Preclinical Development", M. Gerlach, I. Seipelt, L. Blumenstein, K. Jung, T. Schuster, G. Mueller, E. Guenther, J. Engel and M. Teifel. Session: General poster session / division of medicinal chemistry; Dates and time: Sunday, August 19, 2012 from 7pm to 9pm (Eastern); and Monday, August 20, 2012 from 8pm to 10pm (Eastern); Venue: Pennsylvania Convention Center, Hall D
AEZS-136 is an integral part of the Company’s kinase research program
comprising the investigation of different compounds for single Erk
inhibition, single PI3K inhibition and dual Erk/PI3K kinase inhibition.
AEZS-136 selectively inhibits the kinase activity of Erk 1/2 and class
1 PI3Ks, enabling simultaneous inhibition of the Raf-Mek-Erk and the
PI3K-Akt signaling cascades. AEZS-136 was discovered using the
Company’s proprietary compound library and high throughput screening
About Aeterna Zentaris
Aeterna Zentaris is an oncology and endocrinology drug development
company currently investigating treatments for various unmet medical
needs. The Company’s pipeline encompasses compounds at all stages of
development, from drug discovery through to marketed products. For more
information please visit www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.